Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research
In Vitro Assays Show
rBChE Suppresses Amyloid PlaqueFormation ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leadingbiodefense company specializing in the development andcommercialization of medical countermeasures against chemical andbiological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (
rBChE) research program wererecently presented...
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the
Subject of Promising New Alzheimer's Research
In Vitro Assays Show
rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene,Inc., a leading biodefense company specializing in the developmentand commercialization of medical countermeasures against chemicaland biological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (
rBChE) research program wererecently pr...